Cutting-edge biotherapeutics and advanced delivery strategies for the treatment of metabolic dysfunction-associated steatotic liver disease spectrum

Journal of Controlled Release, Journal Year: 2025, Volume and Issue: 380, P. 433 - 456

Published: Feb. 11, 2025

Language: Английский

---

Non-Alcoholic Fatty Liver Disease in Everyday Clinical Practice: From Diagnosis to Therapy

Life, Journal Year: 2025, Volume and Issue: 15(3), P. 363 - 363

Published: Feb. 25, 2025

Non-alcoholic fatty liver disease (NAFLD) is currently one of the most common hepatic disorders observed in daily medical practice [...]

Language: Английский

---

Hepatokines and MASLD: The GLP1-Ras-FGF21-Fetuin-A Crosstalk as a Therapeutic Target

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(19), P. 10795 - 10795

Published: Oct. 8, 2024

The introduction of the term “Metabolic Steatotic Liver Disease” (MASLD) underscores critical role metabolic dysfunction in development and progression chronic liver disease emphasizes need for strategies that address both its comorbidities. In recent years, a liver-focused perspective has revealed altered endocrine function fatty is key contributor to dysregulation observed MASLD. Due secretory capacity, liver’s increased production proteins known as “hepatokines” been linked insulin resistance, explaining why MASLD often precedes other organs ultimately contributes systemic disease. Among these hepatokines, fibroblast growth factor 21 (FGF21) fetuin-A play central roles regulating abnormalities associated with MASLD, their dysregulated secretion response stress implicated This review postulates modulation by GLP1-Ras may mediate beneficial effects drugs, which have attention emerging pharmacotherapy By discussing crosstalk between GLP1-Ras-FGF21-fetuin-A, this hypothesizes possible novel GLP1-FGF21 dual agonist contribute management diseases. Although research needed go into details crosstalk, topic help researchers explore mechanisms type manage

Language: Английский

---

Lactobacillus delbrueckii subsp. lactis CKDB001 Ameliorates Metabolic Complications in High-Fat Diet-Induced Obese Mice

Nutrients, Journal Year: 2024, Volume and Issue: 16(24), P. 4260 - 4260

Published: Dec. 10, 2024

Background/Objectives: Functional probiotics, particularly Lactobacillus delbrueckii subsp. lactis CKDB001, have shown potential as a therapeutic option for metabolic dysfunction-associated steatotic liver disease (MASLD). However, their effects not been confirmed in vivo systems. Here, we investigated the of L. CKDB001 on insulin resistance, dyslipidemia, MASLD, and lipid metabolism murine model high-fat diet (HFD)-induced obesity. Methods: The mice were divided into four groups (n = 12 per group)—normal chow (NCD), high fat (HFD), HFD with (LL), resmetirom (positive control (PC), thyroid receptor β agonist). experimental animals fed NCD or weeks, followed by an additional 12-week oral treatment LL resmetirom. Results: supplementation reduced body weight, levels, HOMA-IR compared those group, indicating improved sensitivity. Additionally, serum triglyceride (TG) levels without affecting total cholesterol (TC) levels. consumption increased weight hepatic TG TC ectopic accumulation; however, reversed these changes, liver-specific effect metabolism. Furthermore, administration attenuated NAFLD activity scores, fibrosis, function markers (aspartate aminotransferase), enhanced Adenosine monophosphate-activated protein kinase (AMPK) phosphorylation. did considerably affect expression genes related to In epididymal adipose tissue, leptin but had no adiponectin; additionally, histological analysis showed increase adipocyte size, potentially linked energy Conclusions: Collectively, findings suggest that could be promising candidate improving sensitivity, reducing accumulation, mitigating MASLD.

Language: Английский

---

Knock-Out of IKKepsilon Ameliorates Atherosclerosis and Fatty Liver Disease by Alterations of Lipid Metabolism in the PCSK9 Model in Mice

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(19), P. 10721 - 10721

Published: Oct. 5, 2024

The inhibitor-kappaB kinase epsilon (IKKε) represents a non-canonical IκB that modulates NF-κB activity and interferon I responses. Inhibition of this pathway has been linked with atherosclerosis metabolic dysfunction-associated steatotic liver disease (MASLD), yet the results are contradictory. In study, we employed combined model hepatic PCSK9D377Y overexpression high-fat diet for 16 weeks to induce steatosis. development atherosclerotic plaques, serum lipid concentrations, metabolism in adipose tissue were compared between wild-type IKKε knock-out mice. formation progression plaques markedly reduced knockout mice, accompanied by cholesterol levels, fat deposition, macrophage infiltration within plaque. Additionally, fatty was diminished these which may be attributed decreased levels multiple species, particularly monounsaturated acids, triglycerides, ceramides serum. modulation several proteins suggests de novo lipogenesis inflammatory response suppressed as consequence inhibition. conclusion, our data suggest is involved mechanisms both MASLD. therefore represent novel approach treatment cardiovascular diseases.

Language: Английский

---

Editorial: Enhancing targeted screening of people living with HIV for liver fibrosis

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 60(10), P. 1453 - 1454

Published: Oct. 17, 2024

LINKED CONTENT This article is linked to Allende et al paper. To view this article, visit https://doi.org/10.1111/apt.18236 .

Language: Английский

---